Is Now a Good Time to Buy Ocugen?
In the coronavirus vaccine market, several players -- including Moderna and Pfizer -- are currently benefiting from a first-mover advantage. But other companies are still looking to break into this space. One of them is Ocugen (NASDAQ: OCGN), a company that partnered with India-based Bharat Biotech to develop and market a COVID-19 vaccine called Covaxin.
Like many other meme stocks, shares of Ocugen have been highly volatile since the beginning of the year -- and a recent regulatory breakthrough in India sent the company's stock soaring through the roof. Let's review what's going on with the vaccine maker and decide whether it is worth initiating a position in its stock today.
Source Fool.com
